Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitric Oxide Gas Inhalation Therapy for COVID-19 Patients
NCT04306393Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2020
- Primary completion
- Dec 2021
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 2
01
Overview
A Phase 2 trial of nitric oxide in coronavirus disease 2019 (COVID-19), sponsored by Massachusetts General Hospital. Started Mar 2020; status: completed.
02
Drugs
nitric oxide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04306393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04306393.